Buy Amitriptilyne

Depression of any etiology. Especially effective in anxiety-depressive states, due to the severity of sedation. Does not cause an exacerbation of productive symptoms (delusions, hallucinations), in contrast to antidepressants with a stimulating effect. - Neurogenic pains of a chronic nature. - Mixed emotional disorders and behavioral disorders, phobic disorders. - Children's enuresis (except for children with hypotonic urinary bladder). - Psychogenic anorexia, bulimic neurosis.

Assign inside (during or after eating). The initial daily intake for oral administration is 50-75 mg (25 mg in 2-3 doses), then the dose is gradually increased by 25-50 mg, until the desired antidepressant effect is achieved. The optimal daily therapeutic dose is 150-200 mg (the maximum part of the dose is taken at night). In severe depression, resistant to therapy, the dose is increased to 300 mg or more, to the maximum tolerated dose (maximum dose for outpatients is 150 mg / day). In these cases, treatment is advisable to start with intramuscular or intravenous administration of the drug, while using higher initial doses, accelerating the build-up of dosages under the control of the somatic condition. After obtaining a stable antidepressant effect in 2-4 weeks, the doses gradually and slowly reduce to 50-100 mg / day and continue therapy for at least 3 months. In case of signs of depression with decreasing doses, it is necessary to return to the previous dose. If the patient's condition does not improve within 3-4 weeks of treatment, then further therapy is impractical.

Amitriptyline strengthens the depressing effect on the central nervous system following drugs: neuroleptics, sedatives and hypnotics, anticonvulsant drugs, analgesics, funds for anesthesia, alcohol; shows synergism when interacting with other antidepressants. With the combined use of amitriptyline with neuroleptics, and / or anticholinergic drugs, a febrile temperature reaction may occur, paralytic intestinal obstruction. Amitriptyline potentiates the hypertensive effects of catecholamines and other adrenostimulants, which increases the risk of heart rhythm disturbances, tachycardia, severe arterial hypertension, but inhibits the effects of drugs that affect norepinephrine release. Amitriptyline may reduce the antihypertensive effect of guanethidine and drugs with a similar mechanism of action, as well as weaken the effect of anticonvulsants. With the simultaneous use of amitriptyline and anticoagulants - derivatives of coumarin or indanedione, an increase in the anticoagulant activity of the latter is possible. With the simultaneous administration of amitriptyline and cimetidine, plasma concentrations of amitriptyline may increase with the possible development of toxic effects. Inducers of microsomal liver enzymes (barbiturates, carbamazepine) reduces plasma concentrations of amitriptyline. Amitriptyline increases the effect of antiparkinsonian drugs, and other drugs that cause extrapyramidal reactions. Quinidine slows the metabolism of amitriptyline. The combined use of amitriptyline with disulfiram and other acetaldehyde dehydrogenase inhibitors can trigger delirium. Estrogen-containing oral contraceptives can increase the bioavailability of amitriptyline; pimozide and probucol may increase cardiac arrhythmias. Amitriptyline may increase depression caused by glucocorticosteroids; joint use with drugs to treat thyrotoxicosis increases the risk of agranulocytosis. Simultaneous reception of amitriptyline with MAO inhibitors can lead to death. A break in treatment between taking MAO inhibitors and tricyclic antidepressants should be at least 14 days!